Approval · Notice of Compliance 35530 · 2025

LONGAVO: Notice of Compliance 35530

Issued June 18, 2025

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 35530
Date: June 18, 2025
Company: Teva Canada LimitedToronto, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Other

Products in this notice

Brand	DIN	Status today
LONGAVO	02558475	Approved
LONGAVO	02558467	Approved
LONGAVO	02558459	Approved
LONGAVO	02558440	Approved

Medicinal ingredients

RISPERIDONE 125 MG per 0.35ML
RISPERIDONE 100 MG per 0.28ML
RISPERIDONE 75 MG per 0.21ML
RISPERIDONE 50 MG per 0.14ML